Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 7Phase 3 5Phase NA 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 132Recurrence 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia 7Immunoglobulin Light-chain Amyloidosis 7Lymphoma, Non-Hodgkin 6Amyloidosis 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Hematologic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Burkitt Lymphoma 5Paraproteinemias 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Acute 4Hematologic Diseases 4Blood Protein Disorders 4Neoplasm Metastasis 3Myelodysplastic Syndromes 3Lymphoma, B-Cell 3Lung Neoplasms 3Esophageal Neoplasms 3Corneal Diseases 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2

Interventions

Cyclophosphamide 18fludarabine phosphate 16Rituximab 16Etoposide 16Peripheral Blood Stem Cell Transplantation 14Brentuximab Vedotin 14fludarabine 11Whole-Body Irradiation 11Nivolumab 11Mycophenolic Acid 11Bendamustine Hydrochloride 11Tacrolimus 10Melphalan 10Filgrastim 9Gemcitabine 8Carboplatin 8Ifosfamide 7Cytarabine 7Cyclosporine 7Busulfan 7pembrolizumab 6Lenalidomide 6Doxorubicin 6Prednisone 5Everolimus 5Antilymphocyte Serum 5Alemtuzumab 5Vinblastine 4Methotrexate 4Mesna 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Hodgkin Disease × Dexamethasone × Clear all
NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Completed
320 enrolled 35 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡